Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Egetis Therapeutics AB ( (SE:EGTX) ) just unveiled an update.
Egetis Therapeutics has received conditional acceptance from the U.S. Food and Drug Administration for Emcitate as the proprietary name of its tiratricol-based treatment for MCT8 deficiency, with final approval tied to the outcome of the ongoing new drug application review. The NDA for Emcitate has Priority Review status and a PDUFA decision date of September 28, 2026, underscoring the potential for the company to expand beyond its existing EU approval and strengthen its position in the rare disease and orphan drug market if U.S. approval is secured.
The Emcitate submission is backed by a comprehensive clinical package, including multiple trials and an expanded access program, and benefits from orphan drug, Breakthrough Therapy and Rare Pediatric Disease designations in the U.S. and EU. A favorable FDA decision could not only bring the first approved treatment for MCT8 deficiency to U.S. patients but may also yield a valuable Priority Review Voucher, enhancing Egetis’s strategic and financial flexibility within the specialty pharma and rare disease landscape.
The most recent analyst rating on (SE:EGTX) stock is a Hold with a SEK5.50 price target. To see the full list of analyst forecasts on Egetis Therapeutics AB stock, see the SE:EGTX Stock Forecast page.
More about Egetis Therapeutics AB
Egetis Therapeutics AB is an innovative, integrated pharmaceutical company focused on late-stage development and commercialization of treatments for serious diseases with significant unmet medical needs in the orphan drug segment. Its lead product Emcitate (tiratricol) targets monocarboxylate transporter 8 (MCT8) deficiency, a rare and highly debilitating condition, and is already approved in the EU, while its pipeline also includes the parked liver-injury candidate Aladote (calmangafodipir).
Average Trading Volume: 842,145
Technical Sentiment Signal: Buy
Current Market Cap: SEK2.24B
For an in-depth examination of EGTX stock, go to TipRanks’ Overview page.